1. FERTILITY PRESERVATION Hesham Al-Inany, M.D, PhD

11. SO WHAT TO DO??

15. Potentially relevant RCTs identified and screened for retrieval (n= 1439) RCTs excluded, Duplicate publication (n=78) RCTs retrieved for more detailed evaluation (n=1361) RCTs excluded Does not fulfill the inclusion criteria (n= 1336) Potentially appropriate RCTs to be included in the meta-analysis (n=25) RCTs excluded from meta-analysis: - GNRH agonist was begun after chemotherapy; no concomitant treatment of GnRH agonist and chemotherapy (n= 6) - Majority of patients had oophorectomy prior to treatment (n= 1) - Ovarian suppression performed reversibly (GnRH agonist for 3 years) or irreversibly (oophorectomy or radiotherapy). Data not provided separately (n= 1) RCTs included in meta-analysis (n=17) RCTs withdrawn, by outcome: - No data available for inclusion (n= 13) RCTs with usable information, by outcome (n= 4)

16. VALUE OF GNRH AGONIST IN REDUCING POF

25. Vitrification 1min, 37 ℃ WS1,2 5min×2 3min DS TS LN 2 Thawing WS + ES1 + ES2 3min ES3 9min VS1 VS2 VS3 VS4 P1 2hrs Cryotop (20μl for each drop, at R.T.) 3min 15sec x 4 Before ICSI (7.5%EG,7.5%DMSO in ES) (15%EG,15%DMSO,0.5M Suc in VS) (1M Suc in TS, 0.5M Suc in DS)

35. Jeruss and Woodruff (2009) New England Journal of Medicine. What Technique is Appropriate ?

37. THANK YOU!